Inhibition of Sphingosine Kinase 2 Results in PARK2-Mediated Mitophagy and Induces Apoptosis in Multiple Myeloma

Curr Oncol. 2023 Mar 4;30(3):3047-3063. doi: 10.3390/curroncol30030231.

Abstract

Mitophagy plays an important role in maintaining mitochondrial homeostasis by clearing damaged mitochondria. Sphingosine kinase 2 (SK2), a type of sphingosine kinase, is an important metabolic enzyme involved in generating sphingosine-1-phosphate. Its expression level is elevated in many cancers and is associated with poor clinical outcomes. However, the relationship between SK2 and mitochondrial dysfunction remains unclear. We found that the genetic downregulation of SK2 or treatment with ABC294640, a specific inhibitor of SK2, induced mitophagy and apoptosis in multiple myeloma cell lines. We showed that mitophagy correlates with apoptosis induction and likely occurs through the SET/PP2AC/PARK2 pathway, where inhibiting PP2AC activity may rescue this process. Furthermore, we found that PP2AC and PARK2 form a complex, suggesting that they might regulate mitophagy through protein-protein interactions. Our study demonstrates the important role of SK2 in regulating mitophagy and provides new insights into the mechanism of mitophagy in multiple myeloma.

Keywords: PARK2; apoptosis; mitophagy; multiple myeloma; sphingosine kinase 2.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Apoptosis
  • Humans
  • Mitochondria / metabolism
  • Mitophagy*
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / genetics

Substances

  • sphingosine kinase
  • sphingosine kinase 2, human
  • parkin protein